<DOC>
	<DOCNO>NCT01780220</DOCNO>
	<brief_summary>As prospective data combination abiraterone salvage radiotherapy , aim study evaluate safety profile abiraterone acetate plus prednisone patient prostate cancer biochemically relapse surgery undergo salvage radiotherapy 6-months LH-RH agonist . The investigator hypothesize toxicity profile treatment potentiate . This study also provide preliminary data efficacy combination .</brief_summary>
	<brief_title>Safety Efficacy Radiotherapy Combined With 6-month LH-RH Agonist Abiraterone Hormone Therapy Treatment Biochemically-relapsing Prostate Cancer Following Surgery</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>1 . Histologically confirm prostate adenocarcinoma 2 . The patient undergone surgery localize prostate adenocarcinoma : pT2 , pT3 pT4 bladder neck involvement 3. pN0 : negative lymphadenectomy time prostatectomy 4 . At inclusion patient clinical sign progressive disease M0 ( bone pelvic scan ) . 5 . ≥ 18 year age life expectancy ≥ 10 year 6 . Performance Status ( ECOG ) ≤ 1 7 . PSA ≤ 0.1 ng/ml prostatectomy ( dosage perform within 2 month surgery ) 8 . PSA ≥ 0.2 ng/ml et ≤ 2 ng/ml time inclusion 9 . Elevation PSA three consecutive assay perform laboratory , minimal interval two month assay , ( PSA nadir level follow two progressive assay ) 10 . At least 6 month surgery biochemical relapse 11 . Serum potassium ≥ 3.5 mmol/L 72 hour first dose abiraterone acetate 12 . Serum creatinine &lt; 1.5 x ULN calculate creatinine clearance ≥ 60 mL/min 13 . Liver function : Serum bilirubin &lt; 1.5 x ULN ( except patient document Gilbert 's disease ) AST ALT &lt; 2.5 x ULN 14 . Patients must affiliate Social Security System . 15 . Patient information write informed consent form sign principal additional research 16 . Patients must willing able comply schedule visit , treatment plan , laboratory test study procedure 1. pN1 : histologicallyproven lymph node involvement initial lymphadenectomy 2 . Histology adenocarcinoma 3 . Previous hormone therapy include prior therapy ketoconazole CYP17 inhibitor ( ) prostate cancer . 4 . Patients treat within last 14 day prior inclusion drug recognize strong inhibitor inducer isoenzyme CYP3A4 ( Clarithromycin , Ketoconazole , Itraconazole , Voriconazole , Ritanovir , see appendix 11 ) require treatment study 5 . Active symptomatic viral hepatitis chronic liver disease 6 . Surgical chemical castration 7 . History cancer , exception basal cell carcinoma cancer treat 5 year inclusion complete remission . 8 . Previous pelvic radiotherapy 9 . Uncontrolled hypertension ( define systolic BP ≥ 140 mmHg diastolic BP ≥ 90 mmHg ) . Patients history hypertension allow provide blood pressure control antihypertensive therapy ( see appendix 10 mandatory BP measurement guideline ) 10 . Severe moderate hepatic impairment ( ChildPugh class B C ) 11 . Patients severe and/or uncontrolled medical disease could compromise participation study , , limit : Clinically significant heart disease evidence myocardial infarction , arterial thrombotic event past 6 month , severe unstable angina , New York Heart Association ( NYHA ) Class III IV heart disease cardiac ejection fraction measurement &lt; 50 % baseline 12 . Known hypersensitivity study drug excipients . 13 . Galactosemia , Glucosegalactose malabsorption lactase deficiency 14 . Patients psychological , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial . 15 . Individual deprive liberty place authority tutor . 16 . Patients already include another therapeutic trial experimental drug give experimental drug within period 30 day .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>abiraterone</keyword>
	<keyword>biochemically-relapsing</keyword>
	<keyword>prostate adenocarcinoma</keyword>
</DOC>